Bolt Biotherapeutics, Inc. — Q1 2021 Form 10-Q
Business context and period: Clinical-stage biotechnology company developing Boltbody immune-stimulating antibody conjugates (ISACs) for cancer. This unaudited report covers the three months ended March 31, 2021; comparisons are with Q1 2020. The company has no approved products and no product sales.
Financial performance and position
- Revenue: Collaboration revenue was $0, down from $164,000. No revenue from product sales.
- Expenses and loss: Research and development expense was $14.1 million versus $6.8 million; general and administrative expense was $4.3 million versus $2.1 million. Operating loss was $18.4 million versus $8.7 million. Net loss was $24.5 million versus $8.6 million; basic and diluted loss per share was $1.14 versus $4.16. The per-share comparison is affected by the substantial increase in shares following the IPO and preferred-stock conversion.
- Margins: Not meaningful given no Q1 2021 revenue and the company’s development-stage operations.
- Cash flow: Operating cash use was $16.6 million versus $9.6 million. Investing cash use was $190.5 million, primarily purchases of marketable securities; financing provided $297.0 million. Cash, cash equivalents and restricted cash increased by $89.9 million to $97.0 million.
- Liquidity: Cash and cash equivalents were $95.5 million; short- and long-term investments totaled $207.4 million. Cash plus investments were approximately $302.9 million at March 31, 2021. Current assets were $271.2 million and current liabilities $12.0 million.
- Debt and other obligations: The company stated it had no outstanding debt. Operating lease liabilities totaled approximately $10.7 million; potential supply-agreement milestone payments were up to $2.0 million.
Material changes and notable items
- Completed its February 2021 IPO of 13.225 million shares at $20 per share, generating approximately $242.0 million net proceeds. Also received $51.9 million net from the January Series C-2 preferred financing. Preferred shares converted to common stock in connection with the IPO.
- R&D expense increased $7.3 million, primarily due to higher manufacturing costs, increased headcount and facility expenses. G&A increased $2.2 million, largely due to personnel and professional-service costs.
- A $6.1 million noncash expense from remeasurement of the preferred-stock purchase-right liability contributed to the net loss; the liability was subsequently settled and reclassified to equity.
- Accumulated deficit was $132.9 million. Stock-based compensation expense increased to $2.1 million from $0.2 million.
Outlook, risks and controls
- Management expected existing cash and marketable securities to fund obligations for at least 12 months after issuance of the statements. It expects continuing operating losses and negative operating cash flows and anticipates needing additional capital; actual runway may differ from the estimate.
- BDC-1001 was in the dose-escalation portion of its Phase 1/2 trial. The company expected to begin Phase 2 dose expansions in key solid-tumor indications in 2021. It anticipated advancing BDC-2034 into clinical testing in 2022 and designating another clinical candidate in the second half of 2021.
- Key risks include clinical and regulatory uncertainty, financing needs, dependence on single-source manufacturers and suppliers, and possible COVID-19-related disruption. Management reported no material financial-statement impact from COVID-19 in the quarter. No material litigation or material changes to previously disclosed risk factors were reported.
- Internal controls: Disclosure controls were not effective due to a material weakness involving insufficient accounting personnel and inadequate formal policies and controls. Remediation efforts had begun; management said the weakness would not be considered remediated until controls had operated effectively for a sufficient period and been tested.
Investor facts to verify
- Clinical-trial progress, safety and efficacy data for BDC-1001, and whether planned trial expansions and candidate milestones occur on schedule.
- Cash burn, investment balances and runway against the company’s stated 12-month funding outlook, including any need for further financing.
- Progress in remediating the material weakness and the effectiveness of resulting financial-reporting controls.
- Manufacturing and supplier continuity, including potential milestone obligations and the timing and costs of development programs.